13% Reduction in dark spot colour intensity after 8 weeks of topical 3% tranexamic acid — measured by colorimetry in a 2024 clinical trial
3+ Distinct mechanisms: anti-melanogenesis, anti-inflammation, anti-angiogenesis — making it one of the more biologically versatile brightening actives
0 Serious adverse effects reported in clinical trials of topical tranexamic acid over 8-week study periods — well-tolerated even on sensitive skin

Why it started in surgery — and ended up in skincare

Tranexamic acid was developed in the 1960s as a drug to reduce surgical bleeding. It works by blocking plasmin, an enzyme that breaks down blood clots. Decades later, dermatologists noticed something unexpected in patients taking it orally: their melasma was improving.

Plasmin also activates arachidonic acid in the skin, which converts into prostaglandins that stimulate melanin production. When UV hits your skin, plasmin activity increases in keratinocytes — the skin cells — triggering this cascade. Tranexamic acid interrupts it at the first step, before melanin production even starts. That is categorically different to how vitamin C works (reducing already-formed melanin) or how niacinamide works (blocking melanin transfer into skin cells).

The result: they're not competing with each other. They're complementary. Layering tranexamic acid with niacinamide or vitamin C gives you multi-pathway pigmentation coverage.

What the clinical evidence actually shows

The strongest evidence is for melasma — the hormonally-linked, UV-triggered pigmentation pattern that appears most often on the upper lip, cheeks, and forehead. Multiple randomised trials have shown topical tranexamic acid reduces melasma severity with a tolerability profile far superior to hydroquinone, which has historically been the standard treatment.

Research note

A 2024 pilot clinical trial published in Cosmetics evaluated 3% topical tranexamic acid over 8 weeks. Colorimetric measurement showed a statistically significant 13% reduction in colour intensity and 6% reduction in spot size. No adverse effects were recorded. These are modest but meaningful numbers for a topical with excellent safety data.

Oral tranexamic acid has stronger effect sizes in studies — but it's a prescription medication, used off-label, with considerations around blood clotting risk that make it unsuitable for everyone. Topical is the accessible, over-the-counter option, and it's where most skincare research is now focused.

Post-inflammatory hyperpigmentation (PIH) — the dark marks left after acne — is less studied. The mechanisms overlap somewhat, but PIH involves inflammation-driven melanin deposition rather than purely UV-triggered production. Some dermatologists use tranexamic acid for PIH with good results; the direct clinical trial data is thinner than for melasma and UV pigmentation.

How to use it in a routine

Look for formulations with 2–5% tranexamic acid. Concentrations used in studies typically sit around 3–5%. Higher concentrations don't necessarily mean better results. Most are applied twice daily — unlike vitamin C, it's stable and doesn't require morning-only use for efficacy reasons.

Practical tip

Apply after cleansing but before moisturiser. If you're using vitamin C in the morning, tranexamic acid layers well on top or can be used in the evening routine instead. The one non-negotiable that makes all brightening actives work: broad-spectrum SPF 30+ every morning. Without it, you're fighting a losing battle.

Tranexamic acid also has anti-redness properties through its anti-angiogenic effect, making it interesting for women with rosacea-adjacent pigmentation or diffuse redness alongside hyperpigmentation. It won't replace dedicated rosacea treatments, but it's one of the few brighteners that addresses redness simultaneously.

🩺

When pigmentation warrants a dermatologist visit

If you have significant melasma that isn't improving with topical actives after 12 weeks, a dermatologist can assess whether prescription oral tranexamic acid, prescription-strength tretinoin, or in-clinic treatments (chemical peels, laser) are appropriate. Any new, changing, or irregular pigmented lesion should be evaluated to rule out skin cancer before beginning self-treatment.

Medical disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making changes to your health routine.

References

  1. Piquero-Casals J, et al. Pilot Clinical Evaluation of Topical 3% Tranexamic Acid for Facial Hyperpigmentation. Cosmetics. 2024;11(5):168. Link
  2. Chen T, et al. Tranexamic Acid for the Treatment of Hyperpigmentation and Telangiectatic Disorders Other Than Melasma. Clinical, Cosmetic and Investigational Dermatology. 2024. PMC
  3. Hakozaki T, et al. The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer. British Journal of Dermatology. 2002;147(1):20–31.